A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension

Bosentan is an effective drug for the treatment of pulmonary arterial hypertension (PAH). The aim of the present meta-analysis was to examine the evidence concerning the efficacy and safety of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type 5 (PDE-5) inhibitors for tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dang, Zhan-Cui, Tang, Bo, Li, Bin, Liu, Shou, Ge, Ri-Li, Li, Zhan-Qiang, Lu, Dian-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878909/
https://www.ncbi.nlm.nih.gov/pubmed/31798703
http://dx.doi.org/10.3892/etm.2019.8142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878909/
https://www.ncbi.nlm.nih.gov/pubmed/31798703
http://dx.doi.org/10.3892/etm.2019.8142

Ejemplares similares